Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 11, 2006, Pages 719-725

  Kanazawa, Shigenori ^a   Yamaguchi, Kazuyuki ^a   Kinoshita, Yoshimi ^a   Komiyama, Yutaka ^a   Muramatsu, Mikiko ^a   Nomura, Shosaku ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

Gefitinib; Non small cell lung cancer; Platelet; Soluble IL 2 receptor; T cell activation

Indexed keywords

GEFITINIB; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; OKT 3; PADGEM PROTEIN; RANTES; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL SECRETION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CHEMOKINE CCL5; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM STAGING; P-SELECTIN; PROGNOSIS; QUINAZOLINES; RANTES; RECEPTORS, INTERLEUKIN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 33748376246     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0120-x     Document Type: Article

References (30)

1. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970
2. Frasci G, Panza P, Comella P, Nicolella GP, Natale M, Pacilo C, Gravina A, Caputi V, Botti G, Comella G (1997) Cisplatin, gemcitabine, and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol 8:1045-1048
3. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Fek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereilova A, Dong RP, Baselga J (2003) Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246
4. Henderson BE, Ross RK, Pike MC (1991) Toward the primary prevention of cancer. Science 254:1131-1137
5. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22:785-794
6. Josimovic-Alasevic O, Feldmeier H, Zwingeberger K, Harms G, Hahn H, Shrisuphanunt M, Diamantstein T (1988) Interleukin-2 receptor in patients with localized and systemic parasitic diseases. Clin Exp Immunol 72:249-254
7. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM (1997) Tumor regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469-477
8. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder J-M (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587-592
9. Kanazawa S, Muramatsu M, Kinoshita Y, Yamaguchi K, Nomura S (2005a) Gefitinib has the potential of activating cell immunity against malignant cells. J Clin Oncol 23:3865-3867
10. Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S (2005b) Gefitinib affects functions of platelets and blood vessels via changes in the prostanoids balance. Clin Appl Thromb Hemost 11:429-434
11. Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y (2000) The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol 7:239-245
12. Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andrac EJ, Asbell SO, Rotman M, Cox JD (1997) Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol 20:435-440
13. Lebeau B, Chastang CL, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lamarie E (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74:38-45
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
15. Marino P, Preatoni A, Fonticoli L, Parodi M, Tarolo GL (1990) Biomarkers and IL-2R in lung cancer. Recenti Prog Med 81:702-704
16. Maurer LH, Herndon JE II, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 15:3378-3387
17. Murakami S, Hirayama R, Satomi A, Okubo K, Matsuki M, Sakata H, Tsuji Y (1997) Serum sIL-2R concentrations in patients with breast cancer. Breast Cancer 4:25-28
18. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM (2004) Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin-2 therapy. Clin Cancer Res 10:4839-4847
19. O'Rourke MA (1997) Historical review of trials with vinorelbine in non-small-cell lung cancer. Oncology 11:20-27
20. Page A, Nakhle G, Mercier C, Verdant A, Page P, Dontigny L, Allard S, Gauthier JJ, Cossette R (1987) Surgical treatment of bronchiogenic carcinoma: the importance of staging in evaluating late survival. Can J Surg 30:96-99
21. Schrum S, Probst P, Fleischer B, Zipfel PF (1996) Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 157:3598-3604
22. Sieminska A (2004) The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients. Pol Merkuriusz Lek 16:188-190
23. Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169-1176
24. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carrol K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537
25. Waldmann TA (1986) The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727-732
26. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250
27. Yamaguchi K, Kanazawa S, Muramatsu M, Kinoshita S, Nomura S (2005) Elevation of plasma RANTES levels and prognosis in patients treated with gefitinib. J Clin Oncol 16S:244s
28. Yano T, Yoshino I, Yokoyama H, Fukuyama Y, Takai E, Asoh H, Ichinose Y (1996a) The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer 15:79-84
29. Yano T, Fukuyama Y, Yokoyama H, Takai E, Tanaka Y, Asoh H, Ichinose Y (1996b) Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer 16:13-19
30. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards R, Headley E, Kim SH, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC (1981) Effect of sodium warfarin on survival in small cell carcinoma of the lung. JAMA 245:831-835